Promising Phase II Results for ASC30
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") has revealed exciting results from its recent Phase II study regarding ASC30, an investigational oral small molecule designed to combat obesity. This 13-week study examined the efficacy and safety of ASC30 in adults facing overweight or obesity challenges, showing a noteworthy placebo-adjusted mean body weight reduction of 7.7%. What sets ASC30 apart is not only its efficacy but its remarkable gastrointestinal (GI) tolerability.
Effective Weight Management
Participants of the study experienced significant weight loss results, with ASC30 tablets demonstrating reductions of 5.4%, 7.0%, and 7.7% for doses of 20 mg, 40 mg, and 60 mg, respectively. This shows a clear dose-dependent effect without any signs of a plateau in weight loss. The baseline body weight and body mass index (BMI) among participants were recorded at 107.3 kg and 38.6 kg/m², respectively, with 80% of participants on the highest dose of ASC30 achieving a minimum weight loss of 5%.
Encouraging Secondary Outcomes
Beyond weight loss, ASC30 also provided secondary benefits, including decreases in cardiovascular risk markers such as total cholesterol and blood pressure. The relationship between the dose and plasma concentration levels suggests that ASC30 may deliver enhanced efficacy as the dosage increases. Participants tolerating this medication showed a vomiting rate that was approximately half of that seen with another comparable medication, orforglipron, indicating improved tolerability.
Study Design and Findings
The study was a randomized, double-blind, placebo-controlled trial, enrolling 125 participants whose BMI met eligibility criteria. By focusing recruitment on individuals with at least one weight-related comorbidity, Ascletis ensured relevant data collection. The primary goal was to compare body weight reduction in subjects taking ASC30 versus those receiving a placebo. Starting doses were carefully escalated, offering a clear pathway for all participants.
Safety and Adverse Events
Safety evaluations revealed a treatment discontinuation rate for adverse events (AEs) of just 4.8%, demonstrating an encouraging safety profile for ASC30. GI-related AEs were predominantly mild to moderate, showcasing ASC30’s manageable side effect spectrum compared to existing alternatives.
Future Development Plans
Dr. Jinzi Jason Wu, Founder and CEO of Ascletis, has expressed enthusiasm about these findings, anticipating further improvements in GI tolerability as dosing protocols evolve in upcoming studies. There are plans in motion to request a meeting with the U.S. Food and Drug Administration (FDA) regarding the next steps for ASC30’s development.
About ASC30
ASC30 is recognized as a unique small molecule GLP-1R agonist, aiming to provide a daily oral treatment solution for weight management issues. Its innovative properties allow for flexible dosing times without food restrictions, which could significantly benefit patient compliance. As development progresses, ASC30 is expected to emerge as a leading candidate in obesity treatment.
About Ascletis Pharma Inc.
Ascletis is dedicated to creating outstanding therapies for metabolic diseases, relying on innovative technologies like the Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). Their pipeline includes several potential game-changing products which aim to reshape chronic weight management approaches.
Frequently Asked Questions
What are the key findings of the ASC30 study?
The ASC30 study demonstrated a placebo-adjusted weight loss of 7.7% over 13 weeks, accompanied by significant improvements in GI tolerability.
What is the dosage of ASC30 used in the study?
Participants were administered three doses: 20 mg, 40 mg, and 60 mg ASC30 tablets, with all showing positive results regarding weight reduction.
How does ASC30 compare with other treatments?
ASC30 exhibited a significantly lower vomiting rate compared to orforglipron, indicating better gastrointestinal tolerability.
What are the next steps for Ascletis regarding ASC30?
Ascletis plans to submit findings to the FDA and request an End-of-Phase II meeting to discuss future development steps for ASC30.
What technologies does Ascletis utilize in drug development?
Ascletis employs cutting-edge technologies like AISBDD and its Ultra-Long-Acting Platform for the development of its therapeutics.
